After treatment, 10 patients lived
egression. 2. Advanced tumours show acute ocular signs like resolved retinal detachment associated with spontaneous regression. The features that are useful in identifying regression become more subtle in younger children. Regression may be difficult to detect below 14 months of age, as insufficient time has passed for clues to develop. As there is a risk of spontaneous reactivation in regressed tumours, careful monitoring is essential in all such cases. Financial disclosure. None 47 RB7 RETINOBLASTOMA PATIENTS WITH CHROMOSOME 13Q DELETIONS HAVE INCREASED CHEMOTHERAPY- RELATED TOXICITIES R.C. Brennan1, 5, I. Qaddoumi1,5, C. Billups2, C. Odom1, T. Douglas3, W. Furman1,5 M.W. Wilson4,6 (rachel.brennan@stjude.org) Department of 1. Oncology, 2. Biostatistics, 3. Surgery and 4. Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA. Department of 5. Pediatrics and 6. Ophthalmology, University of Tennessee Health Science Center, College of Medicine, Memphis, TN, USA Purpose. Five-10% of retinoblastoma (RB) patients with RB1 germline mutations harbor various sized deletions of chromosome 13 (13q-). We reviewed our experience on a single protocol (RET5) to determine if the 13q- genotype influences toxicity for these patients during chemotherapy. Methods. From 2005-2010, 107 RB patients were treated on RET5: stratum A [low stage; Vincristine(V)/Caroboplatin(C)], stratum B [bilateral; subtenon C with either VC/Topotecan or VC/Etoposide(E)], and stratum C (unilateral/ primary enucleation; high risk histology received V/Cyclophosphamide(Cy)/ Doxorubicin(D) or VCyD/VCE) with focal therapy as needed. Twelve/107 patients had 13q- abnormalities (11%). One to two controls matched for age, stratum and treatment (n=16) were identified for each of 9/12 patients. Grade 3/4 hematologic (hemoglobin, platelets, and absolute neutrophil count [ANC]), infectious (febrile neutropenia, bacteremia), and gastrointestinal (GI) toxicities (anorexia/emesis) were reviewed. Results. In patients with 13q-, slow ANC recovery delayed chemotherapy (8/9) more often than in matched controls (9/16), leading to chemotherapy reductions in 4/9 patients compared with 1/16 controls. GI toxicity was more common (4/9 vs. 1/16), leading to cessation of chemotherapy in one 13q- patient. For 13q- patients, those with microdeletions (n=5) had significantly more grade 3/4 toxicities (mean 18.4 events) compared with patients who had macrodeletions (n=5, mean 9 events) (p=0.024). All patients are alive with no evidence of disease at last follow-up (range 4 to 70 months). Conclusions. Patients with retinoblastoma and 13q- abnormalities have more severe chemotherapy-induced toxicities compared to age and therapy matched controls. These patients may require more intensive supportive care during chemotherapy, prophylactic cytokine support and dose-reductions in chemotherapy. Financial disclosure. None 358 RB8 TOPOTECAN IS EFFECTIVE IN ADVANCED INTRAOCU- LAR RETINOBLASTOMA WITH MANAGEABLE TOXIC- ITY Ibrahim Qaddoumi 1,8, Catherine Billups 2, Clinton F. Stewart 3, Jianrong RETINOBLASTOMA Abstracts 37 Wu 2, Katherine Helton 4, Mary McCarville 4, Thomas E. Merchant 4, Rachel Brennan 1, Barrett G. Haik 5,7, Carlos Rodriguez-Galindo 1,8, Matthew W. Wilson 5,6,7. (ibrahim.qaddoumi@stjude.org) Departments of 1. Oncology; 2. Biostatistics; 3. Pharmaceutical Sciences; 4. Radiological Sciences; 5. Surgery; 6. Pathology St. Jude Children’s Research Hospital, Memphis, TN Departments of 7. Ophthalmology (Hamilton Eye Institute) and 8. Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN Dr. Rodriguez-Galindo is currently at Dana-Farber Cancer Institute, Boston, MA Purpose. To evaluate response rate of topotecan in intraocular retinoblastoma (RB). Methods. Patients with bilateral RB in whom at least one eye was Reese-Ellsworth IV or V were eligible to receive window therapy consisted that of 2 courses of vincristine and topotecan (VT with G-CSF support). Patients with ≥ partial response received 3 more courses of VT alternating with 6 courses of vincristine and carboplatin. The topotecan dose started at 3 mg/m2/day, and was adjusted to attain a target systemic exposure of 140 ± 20 ng/ml*hr. Carboplatin was administered to achieve an area under the curve of 6.5 mg/ml/min. The dose of vincristine dose was 0.05 mg/kg if age at diagnosis < 12 months and 1.5mg/m2 if age at diagnosis > 12 months. Results. A total of 27 patients were enrolled with a median age of 8.1 months (range, 0.7 to 22.1 months). Twenty-four of 27 patients responded (88.9%; 95% Blyth-Still-Casella CI, 71.3%-96.9%). Hematologic toxicity in the form of grade 4 neutropenia (n=27), grade 3 anemia (n=19) and grade 3-4 thrombocytopenia (n=16) were observed during the VT window. Thirteen patients developed grade 3 non-hematologic toxicity. G-CSF support was added after treating 10 patients. Patients treated with GCSF (n=17) had a significant shorter duration of grade 4 neutropenia (median, 7 days) compared to patients without G-CSF (n=10) (median, 24 days) (Wilcoxon rank sum test p
- Page 1 and 2: XV th NH City Hotel and Tower Boliv
- Page 3 and 4: List of Congress Meetings of the In
- Page 5: Table of Contents Welcome address K
- Page 8 and 9: Keynote Lectures Lymphoma of the oc
- Page 10 and 11: The venue for the Biannual Meeting
- Page 12 and 13: Buenos Aires Downtown MAP 12 Venue
- Page 15 and 16: MORNING 8.30-10.10 Papers (Moderato
- Page 17 and 18: 50 RES 26 USING THE GLYCOLYTIC INHI
- Page 19 and 20: 2226 RES 4 NOTCH SIGNALING PROMOTES
- Page 21 and 22: a reduction in the number of living
- Page 23 and 24: array further detected copy number
- Page 25 and 26: 615 RES 21 TRB2 AND SKP2 IN THE RET
- Page 27: following treatment with 2-fluorode
- Page 30 and 31: 1909 Rb14 RESULTS OF PATIENTS WITH
- Page 32 and 33: Posters Retinoblastoma 2006 RBp100
- Page 34 and 35: 120 RBp135 MANAGEMENT OF AN ECTOPIC
- Page 38 and 39: Methods. Six cycles of carboplatin
- Page 40 and 41: 1940 RB15 PROTON THERAPY FOR RECURR
- Page 42 and 43: 4. Fluoroscopy for cannula placemen
- Page 44 and 45: Methods. A retrospective chart revi
- Page 46 and 47: Ruth A. Kleinerman1, Chu-ling Yu1,
- Page 48 and 49: 2006 RBp100 RETINOBLASTOMA ASSESSME
- Page 50 and 51: months. Mean delay between beginnin
- Page 52 and 53: not associated with severity of RB.
- Page 54 and 55: Conclusions. During a ten-year peri
- Page 56 and 57: 30 RBp127 TREATMENT MODULATION IN R
- Page 58 and 59: (follow-up 5 years). Two years afte
- Page 61 and 62: 8.30-9.00 Poster presentations ECOp
- Page 63 and 64: Uvea (Moderators: B. Damato, M. Sag
- Page 65 and 66: Morning 8.30-9.00 Poster presentati
- Page 67 and 68: 1621 EC1 EVALUATION OF THE “HEDGE
- Page 69 and 70: Purpose. Ocular surface squamous ne
- Page 71 and 72: (cargusale@yahoo.com) Oncology Serv
- Page 73 and 74: of the tissues most commonly affect
- Page 75 and 76: 2128 RF1 RETINOBLASTOMA David H. Ab
- Page 77 and 78: Ocular Oncology Service, St Barthol
- Page 79 and 80: Arturo Irarrazaval, Pablo Cazon, Os
- Page 81 and 82: A CASE OF TEARING AND SWELLING OF T
- Page 83 and 84: 1849 ECp101 FIVE CASES OF CARCINOMA
- Page 85 and 86: patients. The isolated involvement
- Page 87 and 88:
exudative fluid from the hemangioma
- Page 89:
maximum of 7 rituximab injections.
- Page 92 and 93:
153 UM14 PHENO-GENOTYPIC IDENTIFICA
- Page 94 and 95:
8.30-9.00 Poster presentations UMp1
- Page 96 and 97:
2253 UM1 PRELIMINARY STUDY OF VASCU
- Page 98 and 99:
Purpose. To determine the presence
- Page 100 and 101:
gene expression profile of melanocy
- Page 102 and 103:
the rarity of UM, timely completion
- Page 104 and 105:
C. Metz, T. Gkika, W. Sauerwein, N.
- Page 106 and 107:
Patients in the triamcinolone group
- Page 108 and 109:
1350 Ump101 INDUCED EXPRESSION OF P
- Page 110 and 111:
Purpose. To report the Results of R
- Page 112 and 113:
1547 Ump113 LONG-TERM OBSERVATIONS
- Page 114 and 115:
2038 Ump119 VALUE OF DOPPLER ANALYS
- Page 116:
Methods. A total of 4070 patients w
- Page 119:
First authors Naseripour, Masood No